Not investment advice. Not medical advice. Full disclosure at the bottom.
Age-related anabolic resistance is a real and increasingly studied phenomenon. As adults get older, skeletal muscle can become less responsive to protein intake and exercise stimuli. The timing and severity vary by person, training status, diet, and metabolic health. But the research is consistent enough that, in my view, people starting in their mid-40s should start paying attention before obvious functional decline appears.
That is not meant to alarm you. It is meant to frame what I believe is a significantly underfollowed investment category, because in my view a biology problem that may affect a very large and growing adult population as people age, with no pharmacological therapy yet approved specifically for sarcopenia, and with multiple recent early-stage clinical readouts moving in an encouraging direction, should be getting more attention from longevity investors than it currently is.
That combination is what EverLife Capital exists to find early.
What Is Actually Happening
The mechanism is called anabolic resistance. When you eat protein, your muscle cells activate a signaling cascade called mTORC1. That cascade drives muscle protein synthesis. In younger adults, a standard protein meal produces a strong mTORC1 response and muscle rebuilds efficiently.
As adults age, that response can become blunted. One commonly cited analysis found that older adults required a meaningfully higher per-meal protein dose to maximize muscle protein synthesis compared to younger adults, approximately 0.40 grams per kilogram per meal versus 0.24 grams per kilogram per meal. The evidence supports age-related anabolic resistance as a real phenomenon, and that protein needs may rise meaningfully with age, though the research does not point to a single clean onset age and individual variation is substantial.
The timing matters for a specific reason. Most clinical sarcopenia programs have historically enrolled elderly or institutionalized patients. But the biology of anabolic resistance appears to begin earlier, in people who are still training, still working, still functionally healthy. The opportunity to intervene before significant muscle mass is lost is a different clinical and commercial problem than trying to reverse loss that has already occurred. Most longevity biotech investors are not making that distinction. They are chasing methylation clocks and senolytics. Both are legitimate. But in my view, one of the mechanisms with the fastest clinical feedback loops and clearest near-term drug targets is sitting right here in the muscle cell.
Why This Category May Be Underfollowed
Most institutional biotech investors frame sarcopenia as a geriatric indication. That framing compresses the perceived market size and puts it in a slower regulatory lane. Valuations stay low. Coverage stays thin.
That framing appears to be shifting. Regulatory and trial-design thinking around sarcopenia and obesity-related muscle loss is moving in an actively evolving direction, with increasing attention to body composition and functional performance as clinically meaningful measures. There is still no fully established FDA approval pathway for sarcopenia drugs, and I would not characterize the regulatory environment as clearly settled, but the directional movement in how regulators are engaging with this space is meaningful for companies currently in Phase 2 and 3.
The GLP-1 drug category is accelerating this. Reviews and clinical summaries support that lean body mass can account for roughly 15 to 40 percent of total weight lost with GLP-1 therapies, depending on study and agent, with some studies reporting higher proportions for specific compounds. That is creating a large, documented, measurable muscle-loss population that is neither elderly nor severely sarcopenic, and that is already enrolled in the healthcare system in large numbers. Several companies in this space have now added GLP-1-associated muscle loss as a second indication. That is a signal worth tracking.
How I Evaluate These Companies
I use a 25-Gate scoring system across every company I track at EverLife Capital. Gates are scored 1 to 5. Five gates are veto-level, meaning a score below threshold on any one of them ends the evaluation regardless of every other score. The composite pass threshold for a watchlist position is 3.6. Active allocation requires 3.8 or higher.
Critical gates carry 2x weight in the composite: Gate 1 (Leadership), Gate 2 (Preclinical and Clinical Data Quality), Gate 5 (Market Size), Gate 7 (Competitive Moat), Gate 7b (Endpoint Risk), Gate 9 (Governance), Gate 11 (Acquirability), and Gate 21 (Kill Switch protocol).
What follows is a watchlist-level evaluation, not full deep-diligence scoring. I am flagging the gates that stand out in both directions and being explicit about what I am still waiting to see before any of these moves from watch to serious consideration.
Biophytis (OTC: BPTSY / Euronext Growth Paris: ALBPS)
Biophytis has what they describe as the world's most clinically advanced sarcopenia program. Their compound BIO101, branded Ruvembri, is a 20-hydroxyecdysone-derived small molecule. The company received EMA and Belgian regulatory clearance in August 2025 to initiate a Phase 3 sarcopenia study. The trial is expected to begin in the second half of 2026, with planned enrollment of up to 932 patients across Europe and Asia. A consortium of Asian investors signed a memorandum of understanding in October 2025 committing up to $20 million in phased financing over three years, with $10 million in year one, to fund a Hong Kong joint venture for the Asian program. Biophytis has also launched a separate Phase 2 program targeting GLP-1-associated muscle loss, designed to evaluate BIO101 in patients beginning semaglutide, with knee-extension muscle strength as the primary endpoint.
Gate 5 - Market Size (2x weight): 4.5.
Biophytis estimates its initial target markets span more than 65 million patients across China, Japan, and Europe combined. No approved therapy exists anywhere in those markets. In my view, if the Phase 3 succeeds, this could create a meaningful first-mover commercial position in a category with no existing standard of care. The GLP-1 obesity program, if it generates positive data, expands the addressable population further toward the active middle-aged cohort the L-45 thesis is built around.
Gate 2 - Clinical Data Quality (2x weight): 3.5.
Phase 2 showed meaningful improvement in mobility outcomes in sarcopenic patients. The mechanism, MAS1 receptor agonism, is not a direct mTOR activator, which creates some scientific distance from the core anabolic resistance thesis. The downstream effect on muscle protein synthesis is directionally supportive, but the pathway is less characterized for the healthy-aging population than I want to see before this scores higher. The GLP-1 Phase 2 has not yet reported efficacy data.
Gate 7b - Endpoint Risk: 3.0.
The Phase 3 primary population is clinically sarcopenic patients, older and more impaired than the L-45 prevention market. A positive Phase 3 result in that population does not automatically translate to regulatory or commercial clarity for otherwise healthy adults in their 50s. That endpoint gap is the central investment risk for the L-45 thesis specifically.
Gate 1 - Leadership: 3.0.
CEO Stanislas Veillet has navigated multiple regulatory milestones and structured a significant Asian financing partnership. No headline prior biotech exit on the leadership team. Scientific credentials are solid for the indication. Not a veto, not a high-conviction score.
Gate 9 - Governance: Flag.
The Nasdaq delisting in April 2024 matters for US investors. The company now trades on Euronext Growth Paris and OTC in the US. OTC liquidity is thin, price discovery is unreliable, and exit is structurally harder than a listed position.
What I am waiting for. Enrollment velocity from the Phase 3 SARA trial once it begins, specifically whether European sites are tracking to the communicated timeline. Slow enrollment has killed similar programs before. More importantly, I want preliminary efficacy signals from the GLP-1 Phase 2. If that readout shows meaningful lean mass preservation in a population closer to L-45 than the Phase 3 cohort, this moves from watchlist to serious diligence immediately.
Lipocine (Nasdaq: LPCN)
Lipocine is trading at approximately $15M market cap as of mid-March 2026. Their compound LPCN 1148 received FDA Fast Track Designation for sarcopenia in patients with decompensated cirrhosis. Phase 2 data in that population showed improvement in lean mass and physical function markers.
Gate 5 - Market Size (2x weight): 2.5.
This is where the thesis strains. LPCN 1148's primary clinical population is liver disease patients. That is a real indication with real unmet need, but it is not the healthy-aging muscle preservation market. Sarcopenia is a secondary program inside a company whose lead commercial product is a testosterone replacement therapy and whose most advanced Phase 3 program is in postpartum depression. Sarcopenia is the third story here, not the first.
Gate 10 - Aging Mechanism Specificity: 2.0.
The mechanism is androgen receptor agonism via a testosterone prodrug. Testosterone supports muscle protein synthesis, so the biological logic holds. But this is a hormone-level approach with downstream effects on muscle, not a targeted mTOR pathway intervention addressing anabolic resistance directly. For an L-45 prevention thesis, this scores low.
Gate 11 - Acquirability: 3.5.
This is where Lipocine scores better than the mechanism alone suggests. Their oral delivery platform, which converts complex hormone compounds into once-daily oral dosing, is proprietary. TLANDO is already approved and on market. A larger hormone-therapy company could acquire the platform and the sarcopenia Fast Track designation together. That option value is real even if this is not a core thesis name.
Gate 9 - Governance: 3.0.
Standard Nasdaq small-cap governance. Nothing alarming, nothing exceptional. Ongoing dilution risk given multi-program burn rate.
What I am waiting for. Whether Lipocine pursues a sarcopenia indication in a non-cirrhotic population. If they expand LPCN 1148 to community-dwelling healthy-aging adults, the L-45 case changes. Until then, this stays on the watchlist as a regulatory precedent name. The Fast Track Designation signals FDA willingness to engage on sarcopenia as a standalone clinical indication. That precedent matters for every company working this mechanism, not only Lipocine.
Also On The Watchlist
The two most scientifically compelling programs I am currently monitoring are both private. I am naming them here because the watchlist is not limited to what you can buy today. Part of the value of tracking a category carefully is knowing what to look for when these names eventually seek liquidity.
Epirium Bio (private, San Diego). Their compound MF-300 is a first-in-class 15-PGDH inhibitor. The mechanism works by blocking the enzyme that degrades prostaglandin E2, the signaling molecule your muscle generates in response to exercise. Blocking 15-PGDH allows PGE2 to accumulate, mimicking part of the exercise response at the cellular level. The company reported positive Phase 1 results in early January 2026, including clean safety, target engagement, and pharmacodynamic responses in older adult cohorts consistent with results in younger participants. They completed a Type C FDA meeting and plan Phase 2b enrollment in H2 2026. These are company-reported results and have not yet been independently peer-reviewed. In my opinion, based on available public data, the Phase 1 profile in older adults is among the more credible early-stage datasets I have reviewed in this space. That is my view, not a substantiated clinical claim. Gate 2 scores very high on current public data. Gate 1 requires more digging on the CEO's commercial track record. If Epirium takes a crossover round or files for an IPO ahead of Phase 2b, this goes to full 25-Gate evaluation immediately.
Rejuvenate Biomed (private, Belgium). Their compound RJx-01 combines metformin and galantamine in a proprietary formulation identified by their AI drug discovery platform. Phase 2 in COPD-related sarcopenia is now enrolling, in partnership with the University of Leicester, the NIHR Leicester Biomedical Research Centre, and Wellcome Leap. That institutional partnership structure is a meaningful third-party validation signal. Phase 1b data showed improvements in muscle strength, function, and fatigue resistance in healthy older men with disuse-induced muscle weakness, a population closer to the L-45 cohort than most programs in this category. A second Phase 2 in GLP-1-associated muscle loss is planned. Gate 5 scores well given the GLP-1 tailwind. Gate 7b needs more work because the current COPD Phase 2 population is still older and more impaired than healthy-aging adults. Watch for the GLP-1 trial design when it is disclosed.
Why I Research This the Way I Do
I am 52. I wear an Ultrahuman Ring and read my recovery and body composition data the way other people read the financial news. Last week I had three consecutive days of reduced muscle readiness with normal sleep and normal stress markers. I eat more protein than most people I know. I train consistently. And my body is not responding the way it did at 38.
I cannot tell you what is specifically happening in my case, and my ring data does not diagnose anything. What it does is keep me honest about the question. The science around age-related anabolic resistance is real. The clinical development activity is real. But none of that is a guarantee of efficacy, approval, or return.
What I can tell you is that this is the lens I bring to every company I evaluate at EverLife Capital. Every mechanism has to connect back to what is plausibly changing in an otherwise healthy 45-plus body, not just in a 75-year-old patient population in a clinical ward. I call it the L-45 filter. It is not a marketing angle. It is literally how I decide what earns serious time.
I spent 24 years building CuraDebt into an A+ BBB-rated company. I know how to evaluate business risk. I know how to read structure. And I have come to believe that the next 30 years of my life are a capital allocation problem as much as a biology problem. The companies working the mechanisms that matter for people like me, in the decade where intervention still plausibly matters, are the ones I want to find before the institutional narrative catches up.
That is dual ROI. One return is financial. The other is personal. When they point at the same company, I pay very close attention.
The Framework Behind This Analysis
The 25-Gate Evaluation System in the Founder's Research Bundle includes the full scoring rubric used in this article, the mTOR-pathway section, the L-45 population filter criteria, the veto gate thresholds, and the specific questions I apply to muscle aging companies at each gate. The Microcap Target List includes the names I am currently tracking with the highest composite scores in this category, catalyst dates, and the specific Phase 2 endpoints worth monitoring.
The bundle is $149. If this category is on your radar, that is the most direct path to the actual framework rather than a summary of it. [ https://everlifecapital.com/research-bundle/ ]
-Eric
Disclosure: EverLife Capital is an independent research publication. Articles reflect the author's opinions at the time of publication and are provided for informational and educational purposes only. They are not personalized investment advice, legal advice, or medical advice, and should not be construed as such. At publication, Eric Pemper does not hold positions in any of the public or private companies discussed in this article. He has not received compensation from any issuer, underwriter, dealer, or affiliated third party related to any security discussed. If either of those facts changes at the time of a future article discussing these companies, specific updated disclosure will be provided. Past performance is not indicative of future results. Investing in early-stage biotech involves substantial risk, including total loss of principal. Readers should conduct their own due diligence and consult qualified financial and medical advisors before making any investment or health-related decision.